tiprankstipranks
Trending News
More News >
NRGENE TECHNOLOGIES LTD (IL:NRGN)
:NRGN
Israel Market
Advertisement

Nrgene (NRGN) AI Stock Analysis

Compare
0 Followers

Top Page

IL:NRGN

Nrgene

(NRGN)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
260.00
▲(3.17% Upside)
Nrgene's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, persistent losses, and negative cash flows, which pose significant liquidity risks. The technical analysis suggests a bearish trend with some potential for short-term upward momentum, but valuation metrics remain unattractive due to ongoing losses.

Nrgene (NRGN) vs. iShares MSCI Israel ETF (EIS)

Nrgene Business Overview & Revenue Model

Company DescriptionNRGene Technologies Ltd, an AI genomics company, provides computational tools and develops advanced algorithms in North America, Europe, Middle East, Africa, Asia Pacific, and internationally. It offers software tools; and turnkey solutions to breeding agricultural and food technology companies, academia, research institutes, and agribiotech companies. The company also develops custom panels for various plants including wheat, canola, corn, soybean, maize, etc., as well as cannabis. NRGene Technologies Ltd was incorporated in 2009 and is based in Ness Ziona, Israel.
How the Company Makes MoneyNRGene makes money primarily through the sale of its genomic analysis and breeding solutions to agricultural companies, research institutions, and plant breeders. The company generates revenue by providing subscription-based access to its proprietary software platforms, which enable users to analyze and interpret genomic data effectively. Additionally, NRGene earns income through collaborative projects and partnerships with agricultural firms, where they offer tailored genomic solutions to meet specific needs. These partnerships often involve long-term agreements and may include revenue-sharing models or milestone-based payments. Licensing of proprietary genomic technologies and tools to third parties also serves as a significant revenue stream for the company.

Nrgene Financial Statement Overview

Summary
Nrgene is facing significant financial challenges across income, balance sheet, and cash flow statements. The declining revenue and persistent losses highlight operational inefficiencies, while the balance sheet shows improved but still weak leverage. Persistent negative cash flows pose liquidity risks, suggesting the need for strategic changes to achieve financial stability.
Income Statement
30
Negative
The company has experienced a consistent decline in revenue over the past several years, with a significant decrease from $7.6M in 2019 to $1.29M in 2024. Both EBIT and net income margins are negative, indicating ongoing operational and profitability challenges. The gross profit margin has also been declining, highlighting increased cost pressures or reduced pricing power. These factors collectively suggest weak income statement performance.
Balance Sheet
40
Negative
The balance sheet shows a relatively stable equity base, but the debt-to-equity ratio has improved significantly from negative equity positions in earlier years to a more balanced structure in 2024. However, the equity ratio remains low, indicating a high level of liabilities relative to assets. While the company has managed to reduce total debt, the overall financial health remains fragile.
Cash Flow
35
Negative
The company has consistently reported negative operating and free cash flows, suggesting challenges in generating cash from core operations. The free cash flow has further declined in recent years, reflecting increased capital expenditure or reduced cash generation. The operating cash flow to net income ratio remains negative, indicating cash flow issues. Overall, cash flow performance is poor, with significant risks to liquidity.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.29M2.00M3.16M4.46M7.04M
Gross Profit267.00K901.00K1.71M2.46M4.51M
EBITDA-2.69M-4.53M-5.59M-7.66M-1.75M
Net Income-3.36M-5.24M-6.21M-8.34M-3.15M
Balance Sheet
Total Assets6.00M10.79M17.30M26.36M3.80M
Cash, Cash Equivalents and Short-Term Investments1.37M6.45M12.28M8.85M1.48M
Total Debt288.00K797.00K791.00K3.34M5.08M
Total Liabilities2.00M3.57M5.04M8.68M9.33M
Stockholders Equity3.96M7.21M12.26M17.68M-5.53M
Cash Flow
Free Cash Flow-5.19M-5.58M-7.83M-6.67M-1.44M
Operating Cash Flow-3.56M-3.91M-6.12M-5.57M-1.42M
Investing Cash Flow-1.30M-1.27M12.47M-14.83M-33.00K
Financing Cash Flow-317.00K-410.00K-2.46M27.59M326.00K

Nrgene Technical Analysis

Technical Analysis Sentiment
Negative
Last Price252.00
Price Trends
50DMA
266.60
Negative
100DMA
268.20
Negative
200DMA
285.02
Negative
Market Momentum
MACD
-4.40
Positive
RSI
36.54
Neutral
STOCH
91.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NRGN, the sentiment is Negative. The current price of 252 is below the 20-day moving average (MA) of 266.08, below the 50-day MA of 266.60, and below the 200-day MA of 285.02, indicating a bearish trend. The MACD of -4.40 indicates Positive momentum. The RSI at 36.54 is Neutral, neither overbought nor oversold. The STOCH value of 91.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NRGN.

Nrgene Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
7.23B25.5425.82%2.86%6.43%14.81%
67
Neutral
5.60B22.2232.36%2.87%11.47%26.50%
66
Neutral
457.09M34.533.87%13.93%-25.57%
45
Neutral
33.40M-23.68%31.97%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IL:NRGN
Nrgene
252.00
-56.80
-18.39%
IL:ABRA
Abra
405.30
134.30
49.56%
IL:SNEL
Synel
2,200.00
971.28
79.05%
IL:ONE
One Technologi
8,089.00
3,248.44
67.11%
IL:MTRX
Matrix
11,650.00
4,647.58
66.37%
IL:PHTM
Photomyne
2,269.00
-298.00
-11.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 15, 2025